A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers

• Published in: Chemical research in toxicology 2017-10, Vol.30 (10), p.1823-1834
• Main Authors: Chen, Liuxi, Smith, James, Mikl, Jaromir, Fryer, Ryan, Pack, Frank, Williams, Brad J, Phillips, Jonathan A, Papov, Vladimir V
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - toxicity; Biomarkers - analysis; Chromatography, Liquid; Cisplatin - chemistry; Cisplatin - toxicity; Doxorubicin - chemistry; Doxorubicin - toxicity; Drug Discovery; Enzyme-Linked Immunosorbent Assay; Kidney Diseases - chemically induced; Kidney Diseases - pathology; Male; Mass Spectrometry; Rats; Rats, Sprague-Dawley
• ISSN: 0893-228X; 1520-5010
• DOI: 10.1021/acs.chemrestox.7b00159

Drug-induced kidney injury (DIKI) is a common toxicity observed in pharmaceutical development. We demonstrated the use of label-free liquid chromatography–mass spectrometry (LC–MS) and multiplex liquid chromatography-single reaction monitoring (LC-SRM) as practical extensions of standard immunoassay based safety biomarker assessments for identification of new toxicity marker candidates and for improved mechanistic understanding. Two different anticancer drugs, doxorubicin (DOX) and cisplatin (cis-diamminedichloridoplatinum, CDDP), were chosen as the toxicants due to their different modes of nephrotoxicity. Analyses of urine samples from toxicant treated and untreated rats were compared to identify biochemical analytes that changed in response to toxicant exposure. A discovery (label-free LC–MS) and targeted proteomics (multiplex LC-SRM) approach was used in combination with well established immunoassay experiments for the identification of a panel of urinary protein markers related to drug induced nephrotoxicity in rats. The initial generation of an expanded set of markers was accomplished using the label-free LC–MS discovery screen and ELISA based analysis of six nephrotoxicity biomarker proteins. Diagnostic performance of the expanded analyte set was statistically compared to conventional nephrotoxicity biomarkers. False discovery rate (FDR) analysis revealed 18 and 28 proteins from the CDDP and DOX groups, respectively, exhibiting significant differences between the vehicle and treated groups. Multiplex SRM assays were constructed to more precisely quantify candidate markers selected from the discovery screen and immunoassay experiments. To evaluate the sensitivity and specificity for each of the candidate biomarkers, histopathology severity scores were used as a benchmark for renal injury followed by receiver-operating characteristic (ROC) curve analysis on selected biomarkers. Further examination of the best performing analytes revealed relevant biological significance after consideration of anatomical localization and functional roles. In summary, the inclusion of mass spectrometry together with conventional ELISA based assays resulted in the identification of an expanded set of biomarkers with a realistic potential for providing additional beneficial information in mechanistic investigations of drug induced kidney injury and with similar responsiveness to conventionally applied indicators of renal injury.